Fragment-based drug discovery in academia: Experiences from a tuberculosis programme

[1]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[2]  Sungsam Gong,et al.  A Structural Bioinformatics Approach to the Analysis of nonsynonymous Single nucleotide polymorphisms (nsSNPS) and their Relation to Disease , 2007, J. Bioinform. Comput. Biol..

[3]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[4]  P. Cardona.  New insights on the nature of latent tuberculosis infection and its treatment. , 2007, Inflammation & allergy drug targets.

[5]  J. H. Pereira,et al.  Dbmodeling , 2007, Cell Biochemistry and Biophysics.

[6]  T. Earnest,et al.  Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.

[7]  M. Toscano,et al.  Nanomolar Inhibition of Type II Dehydroquinase Based on the Enolate Reaction Mechanism , 2007, ChemMedChem.

[8]  T. Blundell.  Structure-based drug design. , 1996, Nature.

[9]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[10]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[11]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[12]  David Eisenberg,et al.  Crystal structure of the pantothenate synthetase from Mycobacterium tuberculosis, snapshots of the enzyme in action. , 2006, Biochemistry.

[13]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[14]  P. Alzari,et al.  Molecular Recognition and Interfacial Catalysis by the Essential Phosphatidylinositol Mannosyltransferase PimA from Mycobacteria* , 2007, Journal of Biological Chemistry.

[15]  John Chan,et al.  Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. , 2003, The Lancet. Infectious diseases.

[16]  Ian Collins,et al.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.

[17]  T. Blundell,et al.  The crystal structure of E. coli pantothenate synthetase confirms it as a member of the cytidylyltransferase superfamily. , 2001, Structure.

[18]  James C Sacchettini,et al.  Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis , 2006, Molecular microbiology.

[19]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[20]  S. Klamt,et al.  GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.

[21]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[22]  I. Smith,et al.  Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice , 2000, Molecular microbiology.

[23]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[24]  Bing Chen,et al.  A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis , 2002, Nature Medicine.

[25]  P. Tucker,et al.  Structure-based approaches to drug discovery against tuberculosis. , 2007, Current protein & peptide science.

[26]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[27]  Michael K. Gilson,et al.  Screening Drug-Like Compounds by Docking to Homology Models: A Systematic Study , 2006, J. Chem. Inf. Model..

[28]  R. Schlögl,et al.  The Crystal Structure of ?-VOPO4. , 2006 .

[29]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[30]  Lindsay Sawyer,et al.  The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction , 1999, Nature Structural Biology.

[31]  C. Chung.  The use of biophysical methods increases success in obtaining liganded crystal structures , 2006, Acta crystallographica. Section D, Biological crystallography.

[32]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[33]  I. Charles,et al.  The Mycobacterium tuberculosis shikimate pathway genes: Evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases , 1991, Molecular and General Genetics MGG.

[34]  J. H. Pereira,et al.  Molecular models of protein targets from Mycobacterium tuberculosis , 2005, Journal of molecular modeling.

[35]  G. Holdgate,et al.  Measurements of binding thermodynamics in drug discovery. , 2005, Drug discovery today.

[36]  Sebastian Radestock,et al.  Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..

[37]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[38]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[39]  Peter J Tonge,et al.  Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. , 2007, Current topics in medicinal chemistry.

[40]  Kristiina Takkinen,et al.  Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. , 2008 .

[41]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[42]  Chris Abell,et al.  Inhibition of Mycobacterium tuberculosis Pantothenate Synthetase by Analogues of the Reaction Intermediate , 2008, Chembiochem : a European journal of chemical biology.

[43]  G. Bourenkov,et al.  Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis. , 2006, Journal of molecular biology.

[44]  D. Searls.  Pharmacophylogenomics: genes, evolution and drug targets , 2003, Nature Reviews Drug Discovery.

[45]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[46]  M. Pallen,et al.  Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae. , 2004, FEMS microbiology reviews.

[47]  W. F. de Azevedo,et al.  Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase from Mycobacterium tuberculosis. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[48]  Ralf Flaig,et al.  New light for science: synchrotron radiation in structural medicine. , 2006, Trends in biotechnology.

[49]  R. Slayden,et al.  Mycolic acids: structure, biosynthesis and physiological functions. , 1998, Progress in lipid research.

[50]  Sujata Sharma,et al.  Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis , 2000, Nature Structural Biology.

[51]  James C Sacchettini,et al.  Biochemical and Structural Studies of Malate Synthase fromMycobacterium tuberculosis * , 2002, The Journal of Biological Chemistry.

[52]  James C Sacchettini,et al.  Crystal Structures of Mycolic Acid Cyclopropane Synthases fromMycobacterium tuberculosis * , 2002, The Journal of Biological Chemistry.

[53]  C. González‐Bello,et al.  Progress in type II dehydroquinase inhibitors: From concept to practice , 2007, Medicinal research reviews.

[54]  P. Brennan,et al.  Identification of the Required Acyltransferase Step in the Biosynthesis of the Phosphatidylinositol Mannosides of Mycobacterium Species* , 2003, Journal of Biological Chemistry.

[55]  R. Bentley,et al.  The shikimate pathway--a metabolic tree with many branches. , 1990, Critical reviews in biochemistry and molecular biology.

[56]  S. Franzblau,et al.  5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs. , 2008, Journal of medicinal chemistry.

[57]  Jorng-Tzong Horng,et al.  Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma , 2008, Oncogene.

[58]  D. Sherman,et al.  The Biosynthesis of Cyclopropanated Mycolic Acids in Mycobacterium tuberculosis , 1995, The Journal of Biological Chemistry.

[59]  Alexander A Alex,et al.  Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.

[60]  B. Meyer,et al.  Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. , 2001, Journal of the American Chemical Society.

[61]  David Eisenberg,et al.  A Novel Inhibitor of Mycobacterium tuberculosis Pantothenate Synthetase , 2007, Journal of biomolecular screening.

[62]  Tanya Parish,et al.  The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. , 2002, Microbiology.